NASDAQ:LPTX Leap Therapeutics - LPTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.32 -0.01 (-3.05%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.29▼$0.3450-Day Range$0.32▼$0.7252-Week Range$0.29▼$1.95Volume1.20 million shsAverage Volume553,981 shsMarket Capitalization$31.48 millionP/E RatioN/ADividend YieldN/APrice Target$2.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Leap Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside780.8% Upside$2.80 Price TargetShort InterestBearish9.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.47) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.78 out of 5 starsMedical Sector702nd out of 989 stocksPharmaceutical Preparations Industry337th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingLeap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.80, Leap Therapeutics has a forecasted upside of 780.8% from its current price of $0.32.Amount of Analyst CoverageLeap Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.06% of the outstanding shares of Leap Therapeutics have been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Leap Therapeutics has recently increased by 45.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLeap Therapeutics does not currently pay a dividend.Dividend GrowthLeap Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPTX. Previous Next 2.2 News and Social Media Coverage News SentimentLeap Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Leap Therapeutics this week, compared to 0 articles on an average week.Search Interest22 people have searched for LPTX on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows6 people have added Leap Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Leap Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Leap Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.44% of the stock of Leap Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Leap Therapeutics are expected to grow in the coming year, from ($0.47) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Leap Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Leap Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLeap Therapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Leap Therapeutics (NASDAQ:LPTX) StockLeap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.Read More Receive LPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LPTX Stock News HeadlinesMarch 24, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on Leap Therapeutics (LPTX)March 24, 2023 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 25, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 20, 2023 | markets.businessinsider.comRobert W. Baird Keeps Their Buy Rating on Leap Therapeutics (LPTX)March 20, 2023 | americanbankingnews.comLeap Therapeutics (NASDAQ:LPTX) PT Lowered to $2.00 at MizuhoMarch 16, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Buy Rating for Leap Therapeutics (LPTX)March 16, 2023 | finance.yahoo.comLeap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01March 16, 2023 | uk.finance.yahoo.comLeap Therapeutics, Inc. (LPTX)March 25, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. January 25, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing InvestigationsJanuary 25, 2023 | finance.yahoo.comLeap Therapeutics Shares Fall After Flame Biosciences AcquisitionJanuary 24, 2023 | businesswire.comLPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to ShareholdersJanuary 19, 2023 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. BuyoutJanuary 18, 2023 | msn.comHC Wainwright & Co. Maintains Buy Rating for Leap Therapeutics: Here's What You Need To KnowNovember 21, 2022 | finance.yahoo.comLeap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare ConferenceNovember 16, 2022 | finance.yahoo.comLeap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)November 7, 2022 | finance.yahoo.comLeap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual MeetingOctober 26, 2022 | finance.yahoo.comIs Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?October 19, 2022 | seekingalpha.comLPTX Leap Therapeutics, Inc.October 12, 2022 | finance.yahoo.comLeap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction CancerAugust 16, 2022 | au.finance.yahoo.comLeap Therapeutics Reports Second Quarter 2022 Financial ResultsAugust 12, 2022 | finance.yahoo.comLeap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer InstituteJuly 21, 2022 | finance.yahoo.comDo Institutions Own Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares?July 19, 2022 | benzinga.comLeap Therapeutics (NASDAQ:LPTX), Analyst Ratings, Price Targets, PredictionsMay 19, 2022 | finance.yahoo.comWe're Keeping An Eye On Leap Therapeutics' (NASDAQ:LPTX) Cash Burn RateMay 13, 2022 | finance.yahoo.comLeap Therapeutics Reports First Quarter 2022 Financial ResultsApril 9, 2022 | finance.yahoo.comShareholders in Leap Therapeutics (NASDAQ:LPTX) are in the red if they invested five years agoSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LPTX Company Calendar Last Earnings3/24/2023Today3/25/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPTX CUSIPN/A CIK1509745 Webwww.leaptx.com Phone(617) 714-0360FaxN/AEmployees36Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.80 High Stock Price Forecast$4.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+780.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,590,000.00 Net MarginsN/A Pretax Margin-14,214.93% Return on Equity-59.23% Return on Assets-53.26% Debt Debt-to-Equity RatioN/A Current Ratio6.82 Quick Ratio6.82 Sales & Book Value Annual Sales$1.50 million Price / Sales20.99 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book0.26Miscellaneous Outstanding Shares99,020,000Free Float86,643,000Market Cap$31.48 million OptionableNot Optionable Beta0.75 Key ExecutivesDoug E. OnsiPresident, CEO, CFO, Secretary & TreasurerAugustine J. LawlorChief Operating OfficerCynthia SirardChief Medical OfficerMichael HaasHead-ResearchJason S. BaumVice President & Head-Translational MedicineKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYMEI PharmaNASDAQ:MEIPCorvus PharmaceuticalsNASDAQ:CRVSPalatin TechnologiesNYSE:PTNVistaGen TherapeuticsNASDAQ:VTGNView All CompetitorsInstitutional OwnershipMillennium Management LLCBought 633,666 shares on 2/15/2023Ownership: 1.117%Jane Street Group LLCBought 50,051 shares on 2/15/2023Ownership: 0.183%683 Capital Management LLCBought 485,000 shares on 2/14/2023Ownership: 2.777%Marshall Wace LLPSold 159,948 shares on 2/14/2023Ownership: 0.467%Two Sigma Investments LPBought 98,069 shares on 2/14/2023Ownership: 0.099%View All Institutional Transactions LPTX Stock - Frequently Asked Questions Should I buy or sell Leap Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares. View LPTX analyst ratings or view top-rated stocks. What is Leap Therapeutics' stock price forecast for 2023? 3 brokerages have issued 1-year target prices for Leap Therapeutics' shares. Their LPTX share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 780.8% from the stock's current price. View analysts price targets for LPTX or view top-rated stocks among Wall Street analysts. How have LPTX shares performed in 2023? Leap Therapeutics' stock was trading at $0.45 at the beginning of the year. Since then, LPTX stock has decreased by 29.4% and is now trading at $0.3179. View the best growth stocks for 2023 here. When is Leap Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our LPTX earnings forecast. How were Leap Therapeutics' earnings last quarter? Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings results on Friday, March, 24th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.02. What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK), VYNE Therapeutics (VYNE), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL). What is Leap Therapeutics' stock symbol? Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX." Who are Leap Therapeutics' major shareholders? Leap Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (2.78%), Key Client Fiduciary Advisors LLC (1.36%), Element Capital Management LLC (1.17%), Millennium Management LLC (1.12%), Renaissance Technologies LLC (0.93%) and Knott David M Jr (0.85%). View institutional ownership trends. How do I buy shares of Leap Therapeutics? Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Leap Therapeutics' stock price today? One share of LPTX stock can currently be purchased for approximately $0.32. How much money does Leap Therapeutics make? Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $31.48 million and generates $1.50 million in revenue each year. The company earns $-40,590,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. How can I contact Leap Therapeutics? Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for the company is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com. This page (NASDAQ:LPTX) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.